Physician
Michigan Specialty Clinic PLLC
Michigan Specialty Clinic PLLC was paid $5.04M by Medicaid between Jan 2018 and Sep 2023, across 98 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 47% of everything it billed.
33Billing provider infoMICHIGAN SPECIALTY CLINIC PLLC
DEARBORN, MI 48126
DEARBORN, MI 48126
33aNPI1760700660assigned 05/17/2010
33bProvider typePlastic Surgery Physician
28Total paid$5.04M
24GClaims123,923
24DCodes billed98
24AFirst – last monthJan 2018 – Sep 2023
Compared with peers
Next to other Plastic Surgery Physician providers in Michigan
Rank by total paid#1 of 13
Median peer was paid$48K
This provider vs. median104×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,099 | $502K | |
| 2019 | 16,030 | $588K | |
| 2020 | 22,571 | $877K | |
| 2021 | 32,686 | $1.36M | |
| 2022 | 27,871 | $1.26M | |
| 2023 | 9,666 | $448K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 47% | 38,504 | 31,808 | $2.37M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 19% | 14,022 | 13,940 | $946K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 10,295 | 9,564 | $786K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 3.2% | 1,709 | 1,694 | $162K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 2.3% | 1,400 | 1,393 | $118K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 7,436 | 6,362 | $62K |
| 31231 | 1.1% | 540 | 503 | $58K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 1,415 | 1,309 | $54K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 495 | 487 | $47K |
| 99000 | <1% | 7,637 | 7,032 | $33K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 949 | 911 | $32K |
| 99385 | <1% | 229 | 227 | $23K |
86 more codes
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 122 | $22K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,010 | $18K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 105 | $18K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,253 | $15K |
| 95024 | <1% | 102 | $14K | |
| 99490 | Ccm add 20min | <1% | 1,125 | $14K |
| 93000 | <1% | 1,617 | $14K | |
| 99386 | <1% | 107 | $13K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 245 | $13K |
| 80053 | Comprehensive metabolic panel | <1% | 1,408 | $12K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 904 | $11K |
| 90674 | <1% | 379 | $11K | |
| 99441 | <1% | 647 | $10K | |
| 90756 | <1% | 405 | $10K | |
| Q4177 | Floweramnioflo, 0.1 cc | <1% | 15 | $9K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 96 | $9K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 512 | $9K |
| 90686 | <1% | 417 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 620 | $8K |
| 81002 | <1% | 2,918 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 573 | $7K |
| 82962 | <1% | 2,789 | $7K | |
| 95117 | <1% | 1,013 | $6K | |
| G0008 | Administration of influenza virus vaccine | <1% | 626 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 254 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 780 | $5K |
| 72100 | <1% | 255 | $5K | |
| 70486 | <1% | 63 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 650 | $4K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,560 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,414 | $4K |
| 69210 | <1% | 192 | $4K | |
| 0011A | <1% | 89 | $3K | |
| 73560 | <1% | 175 | $3K | |
| 0012A | <1% | 71 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 310 | $3K |
| 85027 | <1% | 402 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 37 | $2K |
| 80061 | Lipid panel | <1% | 325 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 59 | $2K |
| 82607 | <1% | 282 | $2K | |
| 99442 | <1% | 58 | $2K | |
| 90715 | <1% | 46 | $1K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 70 | $1K |
| 81025 | <1% | 165 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 112 | $960.82 |
| 20610 | <1% | 25 | $780.27 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 24 | $756.39 |
| 20552 | <1% | 27 | $669.35 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 454 | $658.45 |
| 86328 | <1% | 17 | $655.40 | |
| 72040 | <1% | 26 | $462.61 | |
| 99454 | <1% | 14 | $457.03 | |
| 73030 | <1% | 15 | $285.60 | |
| 99457 | <1% | 14 | $265.09 | |
| 81003 | <1% | 143 | $263.24 | |
| 99406 | <1% | 45 | $262.57 | |
| 73120 | <1% | 13 | $239.46 | |
| 94642 | <1% | 12 | $185.75 | |
| 96127 | <1% | 54 | $151.63 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 196 | $150.34 |
| 81001 | <1% | 49 | $137.86 | |
| 92567 | <1% | 14 | $105.56 | |
| 84439 | <1% | 13 | $70.04 | |
| 82746 | <1% | 20 | $65.52 | |
| 84425 | <1% | 13 | $62.76 | |
| 82465 | <1% | 15 | $62.35 | |
| 99072 | <1% | 1,071 | $37.50 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 16 | $27.10 |
| 99051 | <1% | 146 | $17.38 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 73 | $9.29 |
| 3050F | <1% | 24 | $0.12 | |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 191 | $0.01 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 241 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 22 | $0.00 |
| 97803 | 0% | 39 | $0.00 | |
| 3051F | 0% | 55 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 108 | $0.00 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 154 | $0.00 |
| 1111F | 0% | 47 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 41 | $0.00 |
| 3044F | 0% | 182 | $0.00 | |
| 91301 | 0% | 83 | $0.00 | |
| 1036F | 0% | 193 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 13 | $0.00 |
| 97802 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMASRI, FATINA (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Michigan Specialty Clinic PLLC | Dearborn, MI | $13K |
| Michigan Specialty Clinic PLLC | Dearborn, MI | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.